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eMethods 
Data collection: 
The R4S database (http://www.clir-r4s.org/) is a free, open tool that permits de-identified collection and 
correlation of TREC numbers with flow cytometry data and clinical diagnosis, using diagnostic definitions 
of SCID and T cell lymphopenia categories common across programs and guidelines, such as the Primary 
Immunodeficiency Treatment Consortium and the Clinical and Laboratory Standards Institute (Table 1).1-4 
Programs conducting SCID newborn screening were invited to upload data online or to provide equivalent 
de-identified information in a spreadsheet format. 
 
TREC screening methodologies in each program (also see eTable): 
All states performing SCID newborn screening isolated DNA from infant dried blood spots and perform 
quantitative PCR (qPCR) to enumerate T cell receptor excision circles (TRECs). Amplification of a control 
segment of genomic DNA was performed (for either all samples or those requiring repeats) to assess 
sample quality. Absent or low TRECs in samples with adequate amplification of control DNA identified 
infants at risk for SCID as well as non-SCID conditions characterized by low numbers of circulating naïve 
T cells. Samples with TRECs below cutoff level and control PCR below cutoff level (eTable 1) required 
recall of the infant for a new DBS sample.1 Infants for whom 2 or more samples consistently failed to 
demonstrate amplification of both TRECs and control DNA required further evaluation. CLSI has 
published a guide to the methodology of PCR assays for SCID newborn screening.1 However, individual 
programs have adapted the test to reflect their own TREC and control PCR reactions, repeat testing 
strategies and input from immunologists. Program specifics for the interval reported in this study were as 
follows: 
California: As published.1,5 Flow cytometry was obtained within the SCID newborn screening program at a 
single contract lab after one positive or 2 incomplete screening results. Designated immunologists 
interpreted flow results and coordinated further evaluations and care. 
Colorado: DBS specimens containing <40 TRECs/μL were repeated for TREC and β-Actin in duplicate 
using a new punch. Samples that upon repeat had <40 TRECs and >8,000 β-Actin copies/μL were 
presumptive positive, and patients were referred to a clinical immunologist. Samples with <40 TRECs and 
<8,000 β-Actin copies were inconclusive, and second dried blood spots were requested. After 2 samples 
with TRECs <40/μL, a clinical immunologist was contacted to coordinate follow up. 
Connecticut: Assay developed by the U. S. Centers for Disease Control and Prevention (CDC). RNaseP 
was the PCR control. TREC copies <10/μL and RNaseP Cycle threshold (Ct) <28 reflexed to immediate 
immunological evaluation. TREC cutoffs were ≤30/μL for term and ≤25/μL for preterm infants. Samples 
with RNaseP Ct ≥28 were unsatisfactory and additional dried blood spots were requested for re-testing. 
TRECs between 10 and 30/μL required repeat TREC measurement in a new punch before an immunology 
referral. 
Delaware: CDC based assay with RNaseP as the PCR control. Cut-offs were Borderline (17-26 TRECs), 
Abnormal (4-16 TRECs) and Alert (No Ct – 3 TRECs). RNaseP values out of range were considered 
invalid. Samples from premature infants (<38 weeks) that were invalid, or had low TRECs, were repeated 
on a subsequent dried blood spot. Early gestation samples were reported with a qualifier until 38 weeks 
reached.  
Massachusetts: Method as published.1,6,7  
Michigan: Both full-term and pre-term infants with dried blood spot TRECs ≤7 copies/μL and β-Actin Ct 
≤30 referred to a designated immunology clinic for flow cytometry; samples with 7-11 TRECs/μL and β-
Actin Ct ≤30 required a repeat sample. If a second dried blood spot also showed ≤11 TRECs/μL, the infant 
was directed for flow cytometry. The decision to use the same algorithm for both full and pre-term infants 
was based on experiences prior to and following the implementation.8  
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Mississippi: Dried blood spots were sent to PerkinElmer Genetics, Inc., where the same algorithm as in 
California was used, except flow cytometry was not conducted within the screening program, instead by the 
immunologist at the referral center.  
Navajo Nation: Dried blood spots were sent to PerkinElmer Genetics, Inc., where the same algorithm as 
Mississippi was used. 
New York: As published.1,9,10 
Texas: Dried blood spots with initial screen results of <200 TRECs/μL were retested in duplicate. Final 
average TRECs ≤150 and RNaseP Ct ≤28.5 were reported as Abnormal or Borderline, while infants with 
undetectable TRECs and RNsseP Ct ≤28.5 were immediately referred to immunologists. All other non-
normal results required an additional dried blood spot. Samples with TRECs ≤150 and RNaseP Ct >28.5 
were reported as unsatisfactory and repeat specimens requested.  
Wisconsin: As published.1,11,12 
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eTable: Summary of SCID newborn screening methods and definitions of T cell lymphopenia in different states 
 Cali-
fornia 
Colo-
rado 
Con-
necticut 
Dela-
ware 
Massa-
chusetts 
Michi-
gan 
Missis-
sippi 
Navajo 
Nation 
New 
York Texas 
Wis-
consin 
Assay protocola PEb Local Local Local Local Local PE PE Local Local Local 
Genomic control BA BA RP RP RP BA BA BA RP RP BA 
Term infant cutoffs 
TREC/μL blood  
(urgent positive)  
≤25  
(5) <40 
≤30  
(10) 
<27 
(16,3) <252 ≤7 ≤25 ≤25 <125 ≤150 <30 
Pre-term or ill infant cutoffs 
TREC/μL blood “ “ ≤25 “ “ “ “ “ ≤200 ≤110 <25 
Controlc (copy number/μL blood 
or Ct) >10,000 >8,000 Ct <28 Ct <28 ≥4,032 Ct ≤30 >10,000 >10,000 Ct <35 
Ct 
≤28.5 >10,000 
Flow 
cytometry 
cutoffs for 
TCLd 
T cells/μL  <1,500 <1,500 <1,500 <1,500 <2,500 <3,505 <2,500 <1,500 Not defined <1,500 <2,500 
CD4+/CD45RA+ 
naïve T cells/μL  
<50% of 
T cells 
Not 
defined 
<50% of 
T cells 
Not 
defined 
<50% of 
T cells 
Not 
defined 
Not 
defined 
Not 
defined 
Not 
defined 
Not 
defined 
Not 
defined 
aFor more detail, see Methods in the Supplement and CLSI document1 (for algorithms of California, Massachusetts, New York and Wisconsin). 
bAbbreviations: BA, -actin gene positive control for PCR; Ct, cycle threshold; PE, PerkinElmer Genetics, Inc.; RP, RNase P gene positive control for PCR; 
TREC, T cell receptor excision circle.  
cRepeat dried blood spot required if control PCR out of accepted range, whether measured by copy number or Ct. 
dTest panels included complete and differential blood count, total lymphocytes/μL, and cells/μL for CD3, CD4, CD8 T cells, CD19 B cells, CD16/56 NK cells, 
CD4/CD45RA+ and CD8/CD45RA+ naïve cells, and CD4/45RO+ and CD8/CD45RO+ memory cells (or equivalent surface markers). For definitions of T cell 
lymphopenia and criteria for follow-up see Table 4. 
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